Clinical Trial Update: Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating fulvestrant (FASLODEX) as a treatment for postmenopausal women with estrogen receptor-positive breast cancer; the study has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• Faslodex (fulvestrant)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED